First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Sets New 12-Month High – Time to Buy?

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)’s share price reached a new 52-week high on Monday . The company traded as high as $43.01 and last traded at $43.01, with a volume of 189 shares. The stock had previously closed at $42.26.

First Trust Nasdaq Pharmaceuticals ETF Stock Up 1.8%

The firm’s 50 day simple moving average is $38.65 and its 200 day simple moving average is $35.94. The company has a market capitalization of $1.01 billion, a PE ratio of 14.51 and a beta of 0.45.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, June 25th were given a dividend of $0.092 per share. This is a positive change from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.37 dividend on an annualized basis and a yield of 0.9%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 11.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock worth $535,000 after purchasing an additional 2,047 shares in the last quarter. Raymond James Financial Inc. purchased a new position in First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter worth approximately $57,000. Envestnet Asset Management Inc. lifted its stake in First Trust Nasdaq Pharmaceuticals ETF by 2.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 18,132 shares of the company’s stock valued at $517,000 after acquiring an additional 367 shares during the period. Vivaldi Capital Management LP lifted its stake in First Trust Nasdaq Pharmaceuticals ETF by 4.1% during the 3rd quarter. Vivaldi Capital Management LP now owns 9,790 shares of the company’s stock valued at $279,000 after acquiring an additional 384 shares during the period. Finally, NBC Securities Inc. boosted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 33.0% in the 4th quarter. NBC Securities Inc. now owns 1,325 shares of the company’s stock valued at $44,000 after acquiring an additional 329 shares during the last quarter.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.